Core Viewpoint - SNDL Inc. announces the departure of Tyler Robson, President of Cannabis, who is leaving to pursue other opportunities, with Ryan Hellard stepping in as Interim President of Cannabis [1] Group 1: Company Overview - SNDL Inc. is one of the largest vertically integrated cannabis companies in Canada and the largest private-sector liquor and cannabis retailer [2] - The company operates various retail banners including Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, Spiritleaf, and Cost Cannabis [2] - SNDL's consumer-facing cannabis brands include Top Leaf, Contraband, Palmetto, Bon Jak, La Plogue, Versus, Value Buds, Grasslands, Vacay, Pearls by Grön, No Future, and Bhang Chocolate [2] - The company aims to deploy strategic capital through direct and indirect investments and partnerships within the North American cannabis industry [2]

Core Viewpoint - Artelo Biosciences, Inc. has successfully closed a private placement of common stock and warrants, raising approximately $11.0 million in gross proceeds, which will be used for working capital and debt repayment [1][3]. Group 1: Offering Details - The private placement involved 3,188,407 shares of common stock and warrants to purchase up to 6,376,814 shares, priced at $3.45 per share [1]. - H.C. Wainwright & Co. served as the exclusive placement agent for this offering [2]. - The potential additional gross proceeds from the warrants, if fully exercised, could amount to approximately $20.4 million [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated for working capital, general corporate purposes, and repayment of certain bridge debt [3]. Group 3: Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing therapeutics that modulate lipid-signaling pathways, addressing unmet needs in various medical conditions [6].

Core Insights - Lulu's Fashion Lounge Holdings, Inc. reported an 11% increase in gross profit for Q4 2025 compared to Q4 2024, reaching $27.9 million, while gross margin improved by 640 basis points to 44.3% [1][9] - The company experienced a 5% decrease in net revenue to $63.0 million, attributed to an 11% decline in total orders placed, although average order value increased by 6% from $129 to $137 [9] - The net loss for Q4 2025 was $0.4 million, a significant improvement from a net loss of $31.9 million in the same period last year [9] Fourth Quarter 2025 Highlights - Gross profit increased to $27.9 million, with a gross margin of 44.3% [9] - Net revenue decreased to $63.0 million, driven by an 11% decrease in total orders placed [9] - Adjusted EBITDA was $2.6 million, compared to a loss of $3.3 million in the same period last year [9] Fiscal Year 2025 Highlights - Gross profit for the fiscal year decreased by 6% to $122.1 million, but gross margin increased by 200 basis points to 43.2% [9] - Net revenue for the year was $282.3 million, an 11% decrease compared to 2024 [9] - Active customers decreased by 11% to 2.3 million [9] Financial Outlook for 2026 - The company expects first quarter 2026 revenue trends to be sequentially lower than Q4 2025, with negative Adjusted EBITDA anticipated for the first quarter [12] - Net debt is projected to be between $7.5 million and $8.0 million at the end of Q1 2026 [12] - The company aims to drive profitability through margin optimization and a curated assortment mix, expecting improvements in Adjusted EBITDA year-over-year [11][12]

Core Viewpoint - Saia, Inc. is set to release its quarterly financial results on April 30, 2026, before the market opens, followed by a conference call to discuss the results [1]. Group 1: Financial Results Announcement - Saia, Inc. will announce its quarterly financial results on April 30, 2026, before market opening [1]. - A conference call will be held at 10:00 a.m. Eastern Time on the same day to discuss the results [1]. Group 2: Conference Call Participation - Participants can join the conference call by dialing 1-833-890-5317 and should call in five to ten minutes early [2]. - The call will be available via live webcast on the company’s website [2]. - A replay of the call will be accessible two hours after its completion until May 30, 2026, at 11:59 P.M. Eastern Time [2]. Group 3: Company Overview - Saia, Inc. provides a variety of logistics services, including less-than-truckload, brokered truckload, and expedited transportation [3]. - The company operates 213 terminals across the nation, headquartered in Georgia [3].

Core Viewpoint - Village Farms International, Inc. has successfully amended and extended its loan with Farm Credit Canada, improving the interest rate by 50 basis points and extending the maturity date to February 3, 2031, indicating the company's strengthening business position and growth strategy [1][2]. Group 1: Loan Amendment Details - The company improved the interest rate on its loan by 50 basis points, with the current variable interest rate below 7.0% [1]. - The loan's maturity date has been extended by four years to February 3, 2031, with a current balance of US $15.4 million [1]. Group 2: Company Overview - Village Farms is a global leader in cannabis and plant-based consumer packaged goods, with a significant asset portfolio exceeding 7 million square feet of advanced greenhouse and indoor cultivation assets [2]. - The company operates one of the largest EU-GMP certified cannabis facilities in Canada and is a market share leader in dried flower formats, producing high-quality strains like Pure Sunfarms Pink Kush [3]. Group 3: International Operations - In the Netherlands, Village Farms is one of ten licensed operators in the regulated cannabis program [4]. - In the United States, the company's CBDistillery brand is among the largest independent hemp-derived wellness platforms [4]. - The company also has a Clean Energy division that transforms landfill gas into renewable natural gas and holds an equity interest in Vanguard Food LP, focusing on strategic acquisitions in North America [4].

Core Viewpoint - Jasper Therapeutics is advancing its clinical-stage antibody therapy, briquilimab, targeting mast cell-driven diseases, with promising data from recent studies and plans for further clinical trials in chronic spontaneous urticaria (CSU) and asthma [1][2]. Financial Results - For the fourth quarter of fiscal 2025, Jasper reported a net loss of $9.1 million, with a basic and diluted net loss per share of $0.32 [5][10]. - Total operating expenses for the quarter were $15.8 million, which included $11.4 million in research and development and $4.5 million in general and administrative expenses [5][10]. - Cash and cash equivalents as of December 31, 2025, totaled $28.7 million, a decrease from $71.6 million in the previous year [10]. Clinical Development Updates - Briquilimab has shown a 67% complete response rate in additional patients from the BEACON study at 12 weeks, with a mean UAS7 reduction of 31 points [5]. - In the open-label extension study, 75% of CSU participants achieved a complete response or well-controlled disease at 12 weeks [5]. - The company is finalizing dose selection for the Phase 2b portion of its planned Phase 2b/3 study in CSU, with patient enrollment expected to begin in the second half of 2026, pending capital availability [2][5]. Recent Investigations - Jasper completed an internal investigation into the lack of clinical response observed in previous BEACON data, confirming no issues with the drug product and providing recommendations for future studies [5]. - The investigation included a comprehensive review of manufacturing records, patient medical histories, and pharmacokinetics data [5]. Future Prospects - Preliminary data from the ETESIAN study indicated reductions in airway hyperresponsiveness and eosinophilic response after a single 180mg dose of briquilimab, supporting further development in asthma [5]. - Future clinical studies in asthma will depend on the competitive landscape, potential strategic partnerships, and capital availability [5].

Core Viewpoint - Xos, Inc. is participating in the 39th Annual Southern California Facilities Expo to showcase its energy solutions platform, targeting facilities engineering and energy management professionals involved in commercial electrification decisions [1][5]. Group 1: Company Overview - Xos, Inc. is a leader in electric commercial vehicles and mobile charging solutions, focusing on battery-electric fleets for medium- and heavy-duty commercial vehicles [10]. - The company aims to provide cost-efficient and easier-to-maintain electric vehicles compared to internal combustion engine counterparts [10]. Group 2: Product Offerings - Xos energy solutions offer mobile, grid-independent charging infrastructure that can be deployed in days without disrupting existing building systems [2][6]. - The solutions eliminate the costly utility interconnection process, which can delay electrification projects by 6 to 12 months and incur costs of $500,000 or more per site [7]. - Intelligent load management software dynamically distributes power across fleets, preventing demand spikes and protecting facility energy budgets [7]. Group 3: Market Engagement - The Southern California Facilities Expo connects facilities directors, energy managers, and maintenance professionals responsible for approving and implementing EV charging infrastructure [5]. - Xos's participation reflects a strategic investment in reaching decision-makers driving commercial electrification in Southern California [5][9]. - The company aims to demonstrate that electrification does not require extensive construction and can align with energy budget management and compliance targets [8]. Group 4: Compliance and Scalability - Deploying Xos energy solutions can earn compliance points under the WAIRE Program, allowing facilities to convert recurring costs into a one-time capital investment [7]. - The solutions are scalable to match the size and complexity of various facility operations, from logistics warehouses to healthcare campuses [7].

Core Insights - Teladoc Health has appointed Susan Salka to its board of directors, effective immediately, following the retirements of Eric Evans and Thomas McKinley [1] - Salka brings extensive healthcare leadership and governance experience, having previously served as president and CEO of AMN Healthcare Services, where she contributed to significant revenue growth [2] - Salka's appointment is expected to enhance Teladoc's strategic direction in care delivery transformation and value creation [2][4] Company Overview - Teladoc Health is recognized as the global leader in virtual care, focusing on delivering and orchestrating care across various stakeholders, including patients, providers, and health systems [4] - The company aims to improve access to healthcare, drive better outcomes, extend provider capacity, and reduce costs through its innovative virtual care solutions [4] Board Composition - Susan Salka will serve on the audit and compensation committees of the board, bringing her expertise from her tenure at AMN Healthcare, where she was instrumental in the company's strategic success and made 26 acquisitions [2][3] - Salka holds an MBA in Finance and has served on multiple boards, including Parexel International and McKesson Corporation, indicating her strong governance background [3]

Core Viewpoint - Vireo Growth Inc. has announced the effectiveness of its Management Services Agreement (MSA) with PharmaCann, allowing Vireo to manage certain retail assets in Colorado until the closing of the Asset Purchase Agreement (APA), expected in Q2 2026 [1][2][3]. Group 1: Management Services Agreement - The MSA became effective on March 22, 2026, enabling Vireo's affiliate to provide management services related to PharmaCann's retail assets in Colorado until the acquisition closes [2]. - Vireo has placed 90,740,741 subordinate voting shares into escrow with Odyssey Trust Company, which will remain there until the asset acquisition is finalized [2]. Group 2: Company Background - Vireo Growth Inc. was founded in 2014 as a pioneering medical cannabis company, focusing on a disciplined and execution-oriented strategy within the industry [3]. - The company aims to leverage its national portfolio while maintaining a strong local market focus, emphasizing the hiring of industry leaders and strategic capital deployment [3].

Core Insights - Oxbridge Re Holdings Limited reported strong performance in its tokenized reinsurance offerings, with the Balanced Yield Token expected to achieve a 25% return, surpassing its initial target of 20%, while the High Yield Token remains on track for a 42% return [2][8] - The company is preparing for the 2026–2027 contract cycle with new offerings targeting annual returns of 20% and 42% [4][8] - The current market valuation of the company does not fully reflect its balance sheet strength and the earnings potential of its platform [5][11] Financial Performance - For the three months ended December 31, 2025, net premiums earned decreased to $555,000 from $595,000 in the same period of 2024 [11] - Net income for the quarter was $120,000, compared to a net loss of $460,000 for the same quarter in 2024 [13] - Total expenses for the three months increased to $1.04 million from $497,000 in the prior year, primarily due to underwriting losses related to Hurricane Milton [15] - For the year ended December 31, 2025, net loss was $2.08 million, an improvement from a net loss of $2.73 million in 2024 [14] Financial Ratios - The loss ratio increased to 119.9% for the year ended December 31, 2025, from 0% in 2024, due to losses from reinsurance contracts affected by Hurricane Milton [18] - The expense ratio rose to 144.2% for the year ended December 31, 2025, compared to 94.3% in 2024, driven by increased operational costs [20] - The combined ratio for the year increased to 264.1% from 94.3% in the previous year, reflecting higher expenses and underwriting losses [21] Strategic Outlook - The company is expanding its SurancePlus platform through strategic partnerships to enhance global distribution and infrastructure [3][9] - Management is exploring opportunities to extend the tokenization model into high-quality, cash-generating assets, including data center revenue streams [6][11] - The company aims to scale its platform and innovate in product structure as it enters the 2026–2027 contract cycle [7][10]